Wockhardt has received Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from USFDA. The US Food and Drug Administration (USFDA) has granted WCK 4873, a product from their New Drug Discovery program, Qualified Infectious Disease Product (QIDP) status.
This is the third product from Wockhardt to receive this coveted status after WCK 771 and WCK 2349 last year and provides a strong boost to its drug development program.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
